Skip to content

TAG Condemns Illegal, Partisan CDC Cuts Proposed by White House

  • Jason Kirk

TAG condemns the White House’s proposed retroactive $600 million cuts to CDC programs in four states. Because Congress already appropriated these funds, the cuts are illegal and unconstitutional, threatening HIV and public health programs nationwide. Congress must reject these partisan attacks and protect public health funding.

Read more

This Year, Our Board Saw Firsthand What We Are Up Against

  • Jason Kirk

This year revealed how far this administration is willing to go in undermining public health. The White House refused to recognize World AIDS Day. Global and domestic HIV, TB, and HCV programs were directly threatened, and many were terminated. Senior CDC leaders resigned rather than carry out political firings or oversee the degradation of national vaccine guidance. And in August, a vigilante encouraged by political rhetoric fired nearly 500 rounds into the CDC campus in Atlanta and killed a police officer. The President has still not publicly acknowledged the attack.

Read more

New Report Urges Action to Ensure Sustainable, Affordable Supply of Key Vaccine Adjuvants for Global Health Use

  • Dorrit Walsh

Behind many lifesaving vaccines is a fragile supply chain that few people ever see. This new TAG report examines how weaknesses in the production and supply of key vaccine adjuvants (an ingredient that enhances the immune response) can create bottlenecks that threaten global access to vaccines, underscoring the importance of greater market transparency, security, and competitiveness among governments, funders, and pharmaceutical companies.

Read more

TAG and ANEA Coalition Condemn Proposed $2 Billion in Cuts to HIV Funding

  • Dorrit Walsh

Treatment Action Group and ANEA Coalition strongly condemn the House Labor, Health and Human Services proposed $2 billion in federal cuts to domestic HIV programs, including plans that would dismantle the CDC’s Division of HIV Prevention and slash $535 million from the Ryan White HIV/AIDS Program.

Read more

Gilead Deal to Expand Access to Lenacapavir for PrEP Falls Short

  • Dorrit Walsh

TAG recognizes Gilead Science’s announcement that it has issued six voluntary licenses to produce generic lenacapavir for distribution within 120 high HIV burden countries as a first step toward broadening access to this potent preventive drug for millions of people at risk of HIV.

Read more
Back To Top